BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

MannKind Corporation 

28903 North Avenue Paine

Valencia  California  91355  U.S.A.
Phone: 661-775-5300 Fax: 661-775-2081


SEARCH JOBS

View Clinical Trials from BioPharm Insight

MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.

MannKind is focusing on three areas:

  • First, we are continuing to execute the Technosphere® Insulin clinical trial program.
  • Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.
  • Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.

    Our values, like our work, combine the vision of our founder with the pragmatism of the laboratory. Teamwork, communication, trust and respect sum up the way we work and the way we treat our colleagues, while accountability, quality, and execution motivate the results we achieve. Finally, integrity and enthusiasm describe the spirit we bring to our jobs.

    With around six hundred employees and three locations (in California, New Jersey, and Connecticut), we have grown significantly from our founding in 1991. We continue to be a tight-knit community where each of us has a critical role in our success. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better.

    Last Updated: 04-01-2008

     Key Statistics


    Email:
    Ownership: Public

    Web Site: MannKind Corporation
    Employees:
    Symbol: MNKD
     









  •  Company News
    MannKind Corporation (MNKD) Drops As The FDA Delays Decision On Inhaled Insulin Treatment 4/7/2014 7:39:18 AM    More...
    MannKind Corporation (MNKD) Rockets As FDA Panel Backs Inhaled Diabetes Drug Afrezza; Stock Up 73.88% At Market Close (April 2, 2014) 4/2/2014 7:58:18 AM    More...
    FDA Staff Raises Questions About MannKind Corporation (MNKD) Diabetes Device 3/28/2014 7:45:43 AM    More...
    MannKind Corporation (MNKD) to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 11/8/2013 8:52:10 AM    More...
    MannKind Corporation (MNKD) Announces FDA Acknowledgement of Resubmission of New Drug Application for AFREZZA 10/30/2013 7:39:42 AM    More...
    MannKind Corporation (MNKD) to Hold 2013 Third Quarter Financial Results Conference Call on November 4, 2013 10/29/2013 7:02:54 AM    More...
    MannKind Corporation (MNKD) Resubmits New Drug Application to FDA for AFREZZA for the Treatment of Adults With Diabetes 10/14/2013 9:24:35 AM    More...
    MannKind Corporation (MNKD) to Present at Morgan Stanley Global Healthcare Conference 9/4/2013 6:51:55 AM    More...
    MannKind Corporation (MNKD) Satisfies Conditions for $40 Million, Afrezza Met Phase 3 Goals 8/16/2013 7:05:41 AM    More...
    MannKind Corporation (MNKD) Rockets on Positive Drug Data 8/14/2013 6:49:16 AM    More...
    12345678910...